ES2385396T3 - Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos - Google Patents

Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos Download PDF

Info

Publication number
ES2385396T3
ES2385396T3 ES06714491T ES06714491T ES2385396T3 ES 2385396 T3 ES2385396 T3 ES 2385396T3 ES 06714491 T ES06714491 T ES 06714491T ES 06714491 T ES06714491 T ES 06714491T ES 2385396 T3 ES2385396 T3 ES 2385396T3
Authority
ES
Spain
Prior art keywords
peptide
cells
peptides
hla
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06714491T
Other languages
English (en)
Spanish (es)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ES2385396T3 publication Critical patent/ES2385396T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
ES06714491T 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos Expired - Lifetime ES2385396T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
US657527P 2005-02-28
PCT/JP2006/303352 WO2006093030A1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
ES2385396T3 true ES2385396T3 (es) 2012-07-24

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
ES06714491T Expired - Lifetime ES2385396T3 (es) 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos
ES10177960T Expired - Lifetime ES2435650T3 (es) 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos
ES09007549.0T Expired - Lifetime ES2442294T3 (es) 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10177960T Expired - Lifetime ES2435650T3 (es) 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos
ES09007549.0T Expired - Lifetime ES2442294T3 (es) 2005-02-28 2006-02-17 Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos

Country Status (10)

Country Link
US (4) US7919099B2 (enExample)
EP (4) EP2289532A1 (enExample)
JP (3) JP4931154B2 (enExample)
CY (1) CY1112867T1 (enExample)
DK (3) DK1855707T3 (enExample)
ES (3) ES2385396T3 (enExample)
PL (3) PL1855707T3 (enExample)
PT (3) PT2289533E (enExample)
SI (3) SI2289533T1 (enExample)
WO (1) WO2006093030A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
ES2405763T3 (es) * 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
EP1462456A4 (en) 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
EP2289533A1 (en) 2011-03-02
DK2289533T3 (da) 2013-12-02
EP1855707B1 (en) 2012-04-04
PT2289533E (pt) 2013-12-10
US8663647B2 (en) 2014-03-04
SI2095822T1 (sl) 2013-12-31
PL1855707T3 (pl) 2012-08-31
SI2289533T1 (sl) 2013-11-29
CY1112867T1 (el) 2016-04-13
US20110250219A1 (en) 2011-10-13
EP2095822A1 (en) 2009-09-02
EP2095822B1 (en) 2013-10-16
JP4931154B2 (ja) 2012-05-16
PL2289533T3 (pl) 2014-02-28
US8257711B2 (en) 2012-09-04
HK1152873A1 (en) 2012-03-16
HK1133601A1 (en) 2010-04-01
JP4843095B2 (ja) 2011-12-21
JP5789820B2 (ja) 2015-10-07
DK2095822T3 (da) 2014-01-13
EP2289533B1 (en) 2013-09-18
US20120294877A1 (en) 2012-11-22
US20140186381A1 (en) 2014-07-03
PT2095822E (pt) 2013-12-09
ES2442294T3 (es) 2014-02-11
SI1855707T1 (sl) 2012-07-31
JP2012102105A (ja) 2012-05-31
EP2289532A1 (en) 2011-03-02
HK1110529A1 (en) 2008-07-18
ES2435650T3 (es) 2013-12-20
JP2008531463A (ja) 2008-08-14
PT1855707E (pt) 2012-05-25
WO2006093030A1 (en) 2006-09-08
US20090214581A1 (en) 2009-08-27
DK1855707T3 (da) 2012-07-16
EP1855707A1 (en) 2007-11-21
PL2095822T3 (pl) 2014-03-31
JP2010265269A (ja) 2010-11-25
US7919099B2 (en) 2011-04-05

Similar Documents

Publication Publication Date Title
ES2545818T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ES2541863T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
US8663647B2 (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
ES2327040T3 (es) Peptidos kdr y vacunas que los contienen.
ES2459492T3 (es) Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
ES2541325T3 (es) Péptido de epítopo RAB6KIFL/KIF20A y vacunas que contienen el mismo
HK1152873B (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK1110529B (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK1152872A (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK1133601B (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
BR122020021065B1 (pt) Composição farmacêutica e vacina à base de peptídeos para antígenos associados a tumores expressando câncer, exossomo, método in vitro para induzir células apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica e uso de um peptídeo